Advent Venture appoints new operating partner

Nicholson joins from biotech company Chroma Therapeutics, where he was CEO. Prior to this he held senior positions at Celltech Group plc, Oxford Asymmetry, Lonza AG and Amersham International plc.

Advent Life Sciences Fund I, Advent Venture's first dedicated life sciences vehicle, was reopened to accept a new commitment as well as increased investments from existing LPs in July this year.

The fund closed in November 2010 on £75m. The re-up brought the fund to an aggregate amount of £101.3m.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• People
• UK / Ireland
• Advent Venture Partners